{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:14:00Z","timestamp":1788779640752,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","award":["22805"],"award-info":[{"award-number":["22805"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55275-5","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:45:31Z","timestamp":1781185531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating IGF2BP3 enables risk stratification and predicts treatment response in Ewing sarcoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Caterina","family":"Mancarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"De Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Dirignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Maioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Manara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bazzocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gambarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Scotlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"55275_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra2028910","volume":"384","author":"N Riggi","year":"2021","unstructured":"Riggi, N., Suva, M. L. & Stamenkovic, I. Ewing\u2019s sarcoma. N Engl. J. Med. 384, 154\u2013164. https:\/\/doi.org\/10.1056\/NEJMra2028910 (2021).","journal-title":"N Engl. J. Med."},{"key":"55275_CR2","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar, N. et al. Ewing sarcoma: Current management and future approaches through collaboration. J. Clin. Oncol. 33, 3036\u20133046. https:\/\/doi.org\/10.1200\/JCO.2014.59.5256 (2015).","journal-title":"J. Clin. Oncol."},{"key":"55275_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","volume":"400","author":"B Brennan","year":"2022","unstructured":"Brennan, B. et al. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet 400, 1513\u20131521. https:\/\/doi.org\/10.1016\/S0140-6736(22)01790-1 (2022).","journal-title":"Lancet"},{"key":"55275_CR4","doi-asserted-by":"publisher","first-page":"e31551","DOI":"10.1002\/pbc.31551","volume":"72","author":"R Luksch","year":"2025","unstructured":"Luksch, R. et al. Intensified induction Therapy for newly diagnosed, localized skeletal Ewing sarcoma (ISG\/AIEOP EW-1): A randomized, open-label, phase 3, non-inferiority trial. Pediatr. Blood Cancer. 72, e31551. https:\/\/doi.org\/10.1002\/pbc.31551 (2025).","journal-title":"Pediatr. Blood Cancer"},{"key":"55275_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/MOP.0000000000001535","volume":"38","author":"L Elliott","year":"2026","unstructured":"Elliott, L., Loeb, D. M. & Trucco, M. Management of pediatric bone sarcomas. Curr. Opin. Pediatr. 38, 45\u201352. https:\/\/doi.org\/10.1097\/MOP.0000000000001535 (2026).","journal-title":"Curr. Opin. Pediatr."},{"key":"55275_CR6","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1002\/cncr.30627","volume":"123","author":"NM Marina","year":"2017","unstructured":"Marina, N. M. et al. Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the childhood cancer survivor study. Cancer 123, 2551\u20132560. https:\/\/doi.org\/10.1002\/cncr.30627 (2017).","journal-title":"Cancer"},{"key":"55275_CR7","doi-asserted-by":"publisher","first-page":"e27938","DOI":"10.1002\/pbc.27938","volume":"66","author":"J Caruso","year":"2019","unstructured":"Caruso, J., Shulman, D. S. & DuBois, S. G. Second malignancies in patients treated for Ewing sarcoma: A systematic review. Pediatr. Blood Cancer. 66, e27938. https:\/\/doi.org\/10.1002\/pbc.27938 (2019).","journal-title":"Pediatr. Blood Cancer"},{"key":"55275_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/cncr.35108","volume":"130","author":"EH Yang","year":"2024","unstructured":"Yang, E. H., Strohl, H. B. & Su, H. I. Fertility preservation before and after cancer treatment in children, adolescents, and young adults. Cancer 130, 344\u2013355. https:\/\/doi.org\/10.1002\/cncr.35108 (2024).","journal-title":"Cancer"},{"key":"55275_CR9","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1056\/NEJMoa1801109","volume":"378","author":"PR Brock","year":"2018","unstructured":"Brock, P. R. et al. Sodium thiosulfate for protection from Cisplatin-induced hearing loss. N Engl. J. Med. 378, 2376\u20132385. https:\/\/doi.org\/10.1056\/NEJMoa1801109 (2018).","journal-title":"N Engl. J. Med."},{"key":"55275_CR10","doi-asserted-by":"publisher","unstructured":"Ryan, T. D. et al. Cardiovascular toxicity in patients treated for childhood cancer: A scientific statementfrom the American Heart Association. Circulation 151, e926-e943, (2025). https:\/\/doi.org\/10.1161\/CIR.0000000000001308","DOI":"10.1161\/CIR.0000000000001308"},{"key":"55275_CR11","doi-asserted-by":"publisher","first-page":"e2500377","DOI":"10.1200\/PO-25-00377","volume":"9","author":"A Juan Ribelles","year":"2025","unstructured":"Juan Ribelles, A. et al. Recurrent and refractory Ewing sarcoma phase I\/II trials: Current perspective from the euro-Ewing consortium. JCO Precis Oncol. 9, e2500377. https:\/\/doi.org\/10.1200\/PO-25-00377 (2025).","journal-title":"JCO Precis Oncol."},{"key":"55275_CR12","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1200\/JCO.24.00020","volume":"42","author":"PA Meyers","year":"2024","unstructured":"Meyers, P. A. et al. Open-label, multicenter, phase I\/II, first-in-human trial of TK216: A first-generation EWS::FLI1 fusion protein antagonist in Ewing sarcoma. J. Clin. Oncol. 42, 3725\u20133734. https:\/\/doi.org\/10.1200\/JCO.24.00020 (2024).","journal-title":"J. Clin. Oncol."},{"key":"55275_CR13","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1200\/JCO.2000.18.17.3108","volume":"18","author":"SJ Cotterill","year":"2000","unstructured":"Cotterill, S. J. et al. Prognostic factors in Ewing\u2019s tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing\u2019s Sarcoma Study Group. J. Clin. Oncol. 18, 3108\u20133114. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3108 (2000).","journal-title":"J. Clin. Oncol."},{"key":"55275_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/02841860500519760","volume":"45","author":"G Bacci","year":"2006","unstructured":"Bacci, G. et al. Prognostic factors in non-metastatic Ewing\u2019s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol. 45, 469\u2013475. https:\/\/doi.org\/10.1080\/02841860500519760 (2006).","journal-title":"Acta Oncol."},{"key":"55275_CR15","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.21.00358","volume":"39","author":"PJ Leavey","year":"2021","unstructured":"Leavey, P. J. et al. Phase III trial adding vincristine-topotecan-cyclophosphamide to the initial treatment of patients with nonmetastatic Ewing sarcoma: A children\u2019s oncology group report. J. Clin. Oncol. 39, 4029\u20134038. https:\/\/doi.org\/10.1200\/JCO.21.00358 (2021).","journal-title":"J. Clin. Oncol."},{"key":"55275_CR16","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO-25-00157","volume":"43","author":"R Gillani","year":"2025","unstructured":"Gillani, R. et al. Molecular characterization informs prognosis in patients with Localized Ewing sarcoma: A report from the children\u2019s oncology group. J. Clin. Oncol. 43, 3750\u20133759. https:\/\/doi.org\/10.1200\/JCO-25-00157 (2025).","journal-title":"J. Clin. Oncol."},{"key":"55275_CR17","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/2159-8290.CD-14-0622","volume":"4","author":"F Tirode","year":"2014","unstructured":"Tirode, F. et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 4, 1342\u20131353. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0622 (2014).","journal-title":"Cancer Discov"},{"key":"55275_CR18","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/sj.bjc.6600332","volume":"86","author":"CM Hattinger","year":"2002","unstructured":"Hattinger, C. M. et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br. J. Cancer. 86, 1763\u20131769. https:\/\/doi.org\/10.1038\/sj.bjc.6600332 (2002).","journal-title":"Br. J. Cancer"},{"key":"55275_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/onc.2011.317","volume":"31","author":"C Mackintosh","year":"2012","unstructured":"Mackintosh, C. et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 31, 1287\u20131298. https:\/\/doi.org\/10.1038\/onc.2011.317 (2012).","journal-title":"Oncogene"},{"key":"55275_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ijc.24670","volume":"126","author":"D Zambelli","year":"2010","unstructured":"Zambelli, D. et al. Biological indicators of prognosis in Ewing\u2019s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int. J. Cancer. 126, 41\u201352. https:\/\/doi.org\/10.1002\/ijc.24670 (2010).","journal-title":"Int. J. Cancer"},{"key":"55275_CR21","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/annonc\/mdr605","volume":"23","author":"TGP Grunewald","year":"2012","unstructured":"Grunewald, T. G. P. et al. High STEAP1 expression is associated with improved outcome of Ewing\u2019s sarcoma patients. Ann. Oncol. 23, 2185\u20132190. https:\/\/doi.org\/10.1093\/annonc\/mdr605 (2012).","journal-title":"Ann. Oncol."},{"key":"55275_CR22","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1016\/j.ejca.2015.08.020","volume":"51","author":"LG Sand","year":"2015","unstructured":"Sand, L. G. et al. CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients. Eur. J. Cancer. 51, 2624\u20132633. https:\/\/doi.org\/10.1016\/j.ejca.2015.08.020 (2015).","journal-title":"Eur. J. Cancer"},{"key":"55275_CR23","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1158\/1078-0432.CCR-17-2602","volume":"24","author":"C Mancarella","year":"2018","unstructured":"Mancarella, C. et al. Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional tegulator of ewing sarcoma malignancy. Clin. Cancer Res. 24, 3704\u20133716. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2602 (2018).","journal-title":"Clin. Cancer Res."},{"key":"55275_CR24","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/annonc\/mdu249","volume":"25","author":"MT Marino","year":"2014","unstructured":"Marino, M. T. et al. Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression. Ann. Oncol. 25, 2080\u20132086. https:\/\/doi.org\/10.1093\/annonc\/mdu249 (2014).","journal-title":"Ann. Oncol."},{"key":"55275_CR25","doi-asserted-by":"publisher","unstructured":"Dietz, M. S. et al. Optimizing Ewing sarcoma and osteosarcoma biopsy acquisition: A children\u2019s oncology group bone tumor committee consensus statement. J. Natl. Compr. Canc Netw. 23 https:\/\/doi.org\/10.6004\/jnccn.2024.7063 (2024).","DOI":"10.6004\/jnccn.2024.7063"},{"key":"55275_CR26","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1158\/1078-0432.CCR-21-1324","volume":"27","author":"M Krumbholz","year":"2021","unstructured":"Krumbholz, M. et al. Quantification of translocation-specific ctDNA provides an integrating parameter for early assessment of treatment response and risk stratification in Ewing sarcoma. Clin. Cancer Res. 27, 5922\u20135930. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1324 (2021).","journal-title":"Clin. Cancer Res."},{"key":"55275_CR27","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1038\/s41467-021-23445-w","volume":"12","author":"P Peneder","year":"2021","unstructured":"Peneder, P. et al. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nat. Commun. 12, 3230. https:\/\/doi.org\/10.1038\/s41467-021-23445-w (2021).","journal-title":"Nat. Commun."},{"key":"55275_CR28","doi-asserted-by":"publisher","unstructured":"Ranft, A. et al. Potential biomarkers of Ewing sarcoma identified through a Europe-wide analysis of prospectively collected samples. Sci. Rep. 16 https:\/\/doi.org\/10.1038\/s41598-026-43071-0 (2026).","DOI":"10.1038\/s41598-026-43071-0"},{"key":"55275_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12079-020-00567-2","volume":"14","author":"M Sciandra","year":"2020","unstructured":"Sciandra, M. et al. Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma. J. Cell. Commun. Signal. 14, 335\u2013347. https:\/\/doi.org\/10.1007\/s12079-020-00567-2 (2020).","journal-title":"J. Cell. Commun. Signal."},{"key":"55275_CR30","doi-asserted-by":"publisher","first-page":"117727192211326","DOI":"10.1177\/11772719221132693","volume":"17","author":"J Crow","year":"2022","unstructured":"Crow, J. et al. MicroRNA content of Ewing sarcoma derived extracellular vesicles leads to biomarker potential and identification of a previously undocumented EWS-FLI1 translocation. Biomark. Insights. 17, 11772719221132693. https:\/\/doi.org\/10.1177\/11772719221132693 (2022).","journal-title":"Biomark. Insights"},{"key":"55275_CR31","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1111\/cas.16343","volume":"115","author":"K Uotani","year":"2024","unstructured":"Uotani, K. et al. Identification of ENO-1 positive extracellular vesicles as a circulating biomarker for monitoring of Ewing sarcoma. Cancer Sci. 115, 3660\u20133671. https:\/\/doi.org\/10.1111\/cas.16343 (2024).","journal-title":"Cancer Sci."},{"key":"55275_CR32","doi-asserted-by":"publisher","first-page":"1071675","DOI":"10.3389\/fimmu.2023.1071675","volume":"14","author":"P Chen","year":"2023","unstructured":"Chen, P. et al. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer. Front. Immunol. 14, 1071675. https:\/\/doi.org\/10.3389\/fimmu.2023.1071675 (2023).","journal-title":"Front. Immunol."},{"key":"55275_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang, H. et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell. Biol. 20, 285\u2013295. https:\/\/doi.org\/10.1038\/s41556-018-0045-z (2018).","journal-title":"Nat. Cell. Biol."},{"key":"55275_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2018.00178","volume":"9","author":"C Mancarella","year":"2018","unstructured":"Mancarella, C. et al. Insulin-like growth factor 2 mRNA-binding protein 3 influences sensitivity to Anti-IGF system agents through the translational regulation of IGF1R. Front. Endocrinol. (Lausanne). 9, 178. https:\/\/doi.org\/10.3389\/fendo.2018.00178 (2018).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"55275_CR35","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3389\/fonc.2020.00994","volume":"10","author":"C Mancarella","year":"2020","unstructured":"Mancarella, C. et al. Insulin-like growth factor 2 mRNA-binding protein 3 modulates aggressiveness of Ewing sarcoma by regulating the CD164-CXCR4 axis. Front. Oncol. 10, 994. https:\/\/doi.org\/10.3389\/fonc.2020.00994 (2020).","journal-title":"Front. Oncol."},{"key":"55275_CR36","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/s41417-023-00637-8","volume":"30","author":"C Mancarella","year":"2023","unstructured":"Mancarella, C. et al. Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K\/Akt pathway in neighboring cells. Cancer Gene Ther. 30, 1285\u20131295. https:\/\/doi.org\/10.1038\/s41417-023-00637-8 (2023).","journal-title":"Cancer Gene Ther."},{"key":"55275_CR37","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1200\/JCO.2008.19.2542","volume":"27","author":"K Scotlandi","year":"2009","unstructured":"Scotlandi, K. et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J. Clin. Oncol. 27, 2209\u20132216. https:\/\/doi.org\/10.1200\/JCO.2008.19.2542 (2009).","journal-title":"J. Clin. Oncol."},{"key":"55275_CR38","doi-asserted-by":"publisher","unstructured":"Asaftei, S. D. et al. Front-line window therapy with temozolomide and irinotecan in patients with primary disseminated multifocal Ewing sarcoma: Results of the ISG\/AIEOP EW-2 study. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13123046 (2021).","DOI":"10.3390\/cancers13123046"},{"key":"55275_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1080\/0284186X.2018.1449250","volume":"57","author":"E Palmerini","year":"2018","unstructured":"Palmerini, E. et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncol. 57, 958\u2013964. https:\/\/doi.org\/10.1080\/0284186X.2018.1449250 (2018).","journal-title":"Acta Oncol."},{"key":"55275_CR40","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.ejso.2021.02.009","volume":"47","author":"A Righi","year":"2021","unstructured":"Righi, A. et al. Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: A retrospective analysis of available scoring tools. Eur. J. Surg. Oncol. 47, 1778\u20131783. https:\/\/doi.org\/10.1016\/j.ejso.2021.02.009 (2021).","journal-title":"Eur. J. Surg. Oncol."},{"key":"55275_CR41","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00256-018-2966-9","volume":"47","author":"O Kasalak","year":"2018","unstructured":"Kasalak, O. et al. Surveillance MRI for the detection of locally recurrent Ewing sarcoma seems futile. Skeletal Radiol. 47, 1517\u20131522. https:\/\/doi.org\/10.1007\/s00256-018-2966-9 (2018).","journal-title":"Skeletal Radiol."},{"key":"55275_CR42","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/cam4.2002","volume":"8","author":"LM Haveman","year":"2019","unstructured":"Haveman, L. M. et al. The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing sarcoma. Cancer Med. 8, 1086\u20131094. https:\/\/doi.org\/10.1002\/cam4.2002 (2019).","journal-title":"Cancer Med."},{"key":"55275_CR43","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s44321-025-00364-7","volume":"18","author":"V Suresh","year":"2026","unstructured":"Suresh, V. et al. Modelling EWS::FLI1 protein fluctuations reveal determinants of tumor plasticity in Ewing sarcoma. EMBO Mol. Med. 18, 646\u2013676. https:\/\/doi.org\/10.1038\/s44321-025-00364-7 (2026).","journal-title":"EMBO Mol. Med."},{"key":"55275_CR44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fcell.2019.00363","volume":"7","author":"C Mancarella","year":"2019","unstructured":"Mancarella, C. & Scotlandi, K. IGF2BP3 from physiology to cancer: Novel discoveries, unsolved issues, and future perspectives. Front. Cell. Dev. Biol. 7, 363. https:\/\/doi.org\/10.3389\/fcell.2019.00363 (2019).","journal-title":"Front. Cell. Dev. Biol."},{"key":"55275_CR45","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/1753-0407.13378","volume":"15","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. U-shaped association between serum IGF2BP3 and T2DM: A cross-sectional study in Chinese population. J. Diabetes. 15, 349\u2013361. https:\/\/doi.org\/10.1111\/1753-0407.13378 (2023).","journal-title":"J. Diabetes"},{"key":"55275_CR46","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/ijc.32124","volume":"145","author":"S Tschirdewahn","year":"2019","unstructured":"Tschirdewahn, S. et al. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma. Int. J. Cancer. 145, 531\u2013539. https:\/\/doi.org\/10.1002\/ijc.32124 (2019).","journal-title":"Int. J. Cancer"},{"key":"55275_CR47","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/ijc.28808","volume":"135","author":"T Szarvas","year":"2014","unstructured":"Szarvas, T. et al. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. Int. J. Cancer. 135, 1596\u20131604. https:\/\/doi.org\/10.1002\/ijc.28808 (2014).","journal-title":"Int. J. Cancer"},{"key":"55275_CR48","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1158\/1078-0432.CCR-22-2292","volume":"29","author":"P Anderson","year":"2023","unstructured":"Anderson, P. et al. Pilot study of recurrent Ewing\u2019s sarcoma management with Vigil\/Temozolomide\/Irinotecan and assessment of circulating tumor (ct) DNA. Clin. Cancer Res. 29, 1689\u20131697. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2292 (2023).","journal-title":"Clin. Cancer Res."},{"key":"55275_CR49","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.pathol.2024.04.012","volume":"56","author":"SB Ma","year":"2024","unstructured":"Ma, S. B. et al. Laboratory validation and clinical utility of next-generation sequencing-based IGH\/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology. Pathology 56, 982\u2013992. https:\/\/doi.org\/10.1016\/j.pathol.2024.04.012 (2024).","journal-title":"Pathology"},{"key":"55275_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-017-0647-2","volume":"16","author":"Y Zhou","year":"2017","unstructured":"Zhou, Y. et al. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Mol. Cancer. 16, 77. https:\/\/doi.org\/10.1186\/s12943-017-0647-2 (2017).","journal-title":"Mol. Cancer"},{"key":"55275_CR51","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1038\/s41467-022-32796-x","volume":"13","author":"AA Hariri","year":"2022","unstructured":"Hariri, A. A. et al. Improved immunoassay sensitivity and specificity using single-molecule colocalization. Nat. Commun. 13, 5359. https:\/\/doi.org\/10.1038\/s41467-022-32796-x (2022).","journal-title":"Nat. Commun."},{"key":"55275_CR52","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/cncr.35199","volume":"130","author":"GA Colloca","year":"2024","unstructured":"Colloca, G. A. & Venturino, A. Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial-level analysis. Cancer 130, 1773\u20131783. https:\/\/doi.org\/10.1002\/cncr.35199 (2024).","journal-title":"Cancer"},{"key":"55275_CR53","doi-asserted-by":"publisher","first-page":"1598337","DOI":"10.3389\/fonc.2025.1598337","volume":"15","author":"F Zuo","year":"2025","unstructured":"Zuo, F., Tan, Y., Mao, W., Tang, Z. & Luo, T. Clinical prognosis evaluation of alpha-fetoprotein-positive gastric cancer: comprehensive analysis and development of a novel nomogram for survival prediction. Front. Oncol. 15, 1598337. https:\/\/doi.org\/10.3389\/fonc.2025.1598337 (2025).","journal-title":"Front. Oncol."},{"key":"55275_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-025-04143-2","author":"J Uhlig","year":"2025","unstructured":"Uhlig, J., Kroencke, T. & Kim, H. S. Retrospective clinical studies in interventional oncology: Relevance and challenges. Cardiovasc. Intervent Radiol. https:\/\/doi.org\/10.1007\/s00270-025-04143-2 (2025).","journal-title":"Cardiovasc. Intervent Radiol."},{"key":"55275_CR55","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/oncolo\/oyae162","volume":"29","author":"Y Cao","year":"2024","unstructured":"Cao, Y., Chen, R. C. & Katz, A. J. Why is a small sample size not enough? Oncologist 29, 761\u2013763. https:\/\/doi.org\/10.1093\/oncolo\/oyae162 (2024).","journal-title":"Oncologist"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55275-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55275-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55275-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:05:17Z","timestamp":1788779117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55275-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55275"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55275-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical committee approval was obtained from the Comitato Etico di Area Vasta Emilia Centro (Codice CE AVEC 505\/2019\/Sper\/IOR). Informed consent was obtained for all patients. The study was conducted in accordance with the Declaration of Helsinki ethical guidelines.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Specific written consents for the two case reports here presented were obtained from the patient and patient\u2019s next of kin.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27867"}}